Workplace Drug Testing: An Employer Compliance Guide
DOT vs non-DOT testing, panels and methods, marijuana state-law conflicts, and how to keep a drug-testing program defensible.
- DOT methods
- Urine + oral fluid (49 CFR Part 40)
- Non-DOT
- Governed by state law
- MRO review
- Recommended for defensibility
Workplace drug testing divides into DOT-regulated testing, which must follow the prescriptive procedures in 49 CFR Part 40, and non-DOT testing, which is governed by a patchwork of state laws that vary widely on what employers may test for and when.
A defensible program starts with a written policy that defines which tests apply to which roles, uses certified laboratories and a Medical Review Officer, and is applied consistently to limit discrimination claims.
State marijuana laws are the fastest-moving variable: a growing number of states restrict adverse action based on off-duty cannabis use or positive THC tests, so policies should be reviewed with counsel. Oral-fluid testing is now an authorized DOT method, expanding options beyond urine.
DOL compliance checklist
- Adopt a written drug-testing policy — Define covered roles, test types, and the consequences of a positive result.
- Separate DOT and non-DOT programs — DOT testing must follow 49 CFR Part 40 exactly — keep it distinct from any non-DOT testing.
- Account for state marijuana laws — Several states protect off-duty cannabis use; align your policy with current state law.
- Use certified labs and an MRO — SAMHSA-certified laboratories and Medical Review Officer review keep results defensible.
- Apply testing consistently — Uniform application across similarly situated employees reduces discrimination risk.
A starting point, not legal advice — verify against the primary sources cited below and current rules for your jurisdiction.
Latest DOL coverage
Frequently Asked Questions
No. The hearing is an evidence-gathering proceeding, not a final rule. Until a final order is published, recreational marijuana remains Schedule I and all existing employer drug testing authority is unchanged.
The April 2026 DOJ order moved FDA-approved and state-licensed medical marijuana to Schedule III immediately. The June 29 hearing addresses whether adult-use (recreational) cannabis should also be rescheduled—no final decision has been made on that question yet.
Yes. DOT drug testing requirements are set by statute and regulation independent of CSA scheduling. Even if recreational marijuana moves to Schedule III, DOT-regulated employers must continue testing for THC unless Congress or DOT changes the rule.
Employers should audit current policy language that references marijuana's Schedule I status, monitor state law changes taking effect July 1, 2026, and prepare contingency language that ties prohibitions to impairment and safety rather than scheduling classification alone.
The hearing runs through July 15, 2026. After that, the administrative law judge will issue recommended findings, and the DEA Administrator will publish a final rule—a process that could take several additional months.